azd4635
azd4635: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: AC Immune SA (ACIU)
Development Pipeline (1)
| Company | Phase |
|---|---|
| AC Immune SA (ACIU) | Phase 1/Phase 2 |
Clinical Trials (1)
A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC
Frequently asked questions
Who is developing azd4635?
azd4635 is being developed by AC Immune SA.
How many clinical trials involve azd4635?
BioSniper tracks 1 clinical trial involving azd4635.
Analyze AC Immune SA & azd4635 with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company